奥斯汀科技集团 OST 深 沪
已收盘 12-12 16:00:00 美东时间
1.695
0.000
0.00%
华盛通- 最 高0.00
- 今 开0.00
- 成交量 0股
- 最 低 0.00
- 昨 收 1.695
- 总市值 902.62万
- 52周最高 235.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.4905
- 委 比 0.00%
- 总股本 532.52万
- 历史最高 11947.50
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.75
- 每 手 1
- 风险率 49.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多日本移动出行展揭幕，多家车企发布战略级电动车新品
日本移动出行展（Japan Mobility Show 2025）于10月29日在东京开幕，共有517家企业和机构参展，规模创历史新高。各大车企集中推出面向...
10-30 16:24
Keurig Dr Pepper CEO Reveals What's Next After Raising Sales Outlook
KDP reports strong Q3 2025 results, raises full-year net sales outlook and reaffirms EPS guidance. Shares up on Monday.
10-27 19:38
KDP Discusses Strategy, Leadership and Financing for Upcoming Transformational Transactions
At Investor Day, outlines conviction in the JDE Peet's acquisition and robust plans to execute integration and separation Announces capital-efficient $7 billion strategic investment co-led b...
10-27 19:18
OS Therapies Reports Additional Survival Data For OST-HER2 In Phase 2b Osteosarcoma Trial
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced additional overall and event free survival data
10-22 21:20
Ostin Technology Group Announces Leadership Changes Amid Legal Proceedings
The latest update is out from Ostin Technology Group Co., Ltd. ( ($OST) ). On O...
10-22 02:17
【太平洋医药】医药生物行业周报：板块交投活跃度维持，关注业绩期跷跷板效应
（来源：市场投研资讯） 摘要 本周观点&投资建议 本周医药板块下跌2.48%，跑输沪深300指数0.26pct。板块内部来看，子板块中药店、中药、仿...
10-21 11:37
BRINKER INTERNATIONAL, INC. TO HOST FIRST QUARTER FISCAL 2026 EARNINGS CALL
DALLAS, Oct. 15, 2025 /PRNewswire/ -- Brinker International, Inc. (NYSE: EAT) has scheduled its earnings conference call at 10 a.m. Eastern Time on Wednesday, October 29, 2025, to review fir...
10-16 04:30
OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate
OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA following positive Phase 2b results.
10-10 22:40
